A genetic variant of the CC-A genetic variant of the CC-chemokine CCL2 is associated with chemokine CCL2 is associated with renal function decline in PREVENDrenal function decline in PREVEND
Mike W. Zuurman, Inter.Med./Nephrology, UMC Groningen4-1-2006
Breedtestrategie
Renal function: determinants
Breedtestrategie
-age
-blood pressure
-smoking
-inflammatory state
-sex?
Sex differences in renal pathologyBreedtestrategie
Park et al. JBC 279, 50:52282- 2004
A murine example:
Females Males
Sex differences in renal pathologyBreedtestrategie
Renal function: determinants
Observed differences between males and females in renal pathologyunderline importance of separating by sex in analyses of renal function
Breedtestrategie
Sex
Renal function: determinants
Breedtestrategie
Inflammatory state
1. Albuminuria (proteinuria)
2. CCL2 -2518 pro-inflammatory genotype
Chemokines and their receptors: families
Classified based on position of conserved cystein residuesin the protein structure
Chemokine functions
-Intercellular communication (brain)
-Angiogenesis (f.i. tumour related)
-Orchestration of the immune response * Pro- and anti-inflammatory
-Hematopoiesis
-Organogenesis
-Ovulation, luteal regression
Breedtestrategie
Chemokines in pathology: renal disease
J Am Soc Nephrol 11:152-176, 2000
Breedtestrategie
Breedtestrategie
CCL2
-Monocyte chemoattractant protein-1
-CC-chemokine(group of chemokines that are chemoattractants for lymphocytes, monocytes, eosinophils, basophils, but not neutrophils.)
-Pro-inflammatory
-Leukocyte recruitment
-Angiogenesis
Chemokines in pathology: renal diseaseBreedtestrategie
Association between circulating monocyte chemoattractant protein-1 and urinary albumin excretion in nonobese Type 2 diabetic patients, J Diabetes Complications. 2006 Mar-Apr;20(2):98-104.
CCL2 in renal pathology
Monocyte chemoattractant protein-1 promotes the development of diabetic renal injury in streptozotocin-treated mice, Kidney Int. 2006 Jan;69(1):73-80.
Reactive oxygen species-mediated signaling pathways in angiotensin II-induced MCP-1 expression of proximal tubular cells. Antioxid Redox Signal. 2005 Sep-Oct;7(9-10):1261-8.
Renal response to repetitive exposure to heme proteins: chronic injury induced by an acute insult. Kidney Int. 2000 Jun;57(6):2423-33.
Breedtestrategie
Letendre et al. J Neuroimmunol. 2004 Dec;157(1-2):193-6.
HIV: CCL2 CSF up, plasma trend
CCL2 -2518 A/G functional expression consequences
CCL2 plasma up in AD patients
Breedtestrategie
Fenoglio et al.Neurobiol Aging. 2004 Oct;25(9):1169-73.
MS: CCL2 plasma trend (P=0.08)
Tissue Antigens. 2004 Jul;64(1):70-3
The polymorphism of monocyte chemoattractant protein-1 is associated with the renal disease of SLE. Kim HL, Lee DS, Yang SH, Lim CS, Chung JH, Kim S, Lee JS, Kim YS. Am J Kidney Dis. 2002 Dec;40(6):1146-52.
Monocyte chemoattractant protein-1 A-2518G gene polymorphism and renal survival of Japanese patients with immunoglobulin A nephropathy. Mori H, Kaneko Y, Narita I, Goto S, Saito N, Kondo D, Sato F, Ajiro J, Saga Clin Exp Nephrol. 2005 Dec;9(4):297-303.
Association of the MCP-1 gene polymorphism A-2518G with carpal-tunnel syndrome in hemodialysis patients. Omori K, Kazama JJ, Song J, Goto S, Takada T, Saito N, Sakatsume M, Narita I, Gejyo F. Amyloid. 2002 Sep;9(3):175-82.
A Monocyte chemoattractant protein-1 (MCP-1) polymorphism and outcome after renal transplantation. Kruger B, Schroppel B, Ashkan R, Marder B, Zulke C, Murphy B, Kramer BK, Fischereder M. J Am Soc Nephrol. 2002 Oct;13(10):2585-9.
CCL2 -2518 in renal pathology
Breedtestrategie
Breedtestrategie
Kruger et al. J Am Soc Nephrol. 2002 Oct;13(10):2585-9.
Renal function: determinants
Breedtestrategie
Inflammatory state
1. Albuminuria (proteinuria)
2. CCL2 -2518 pro-inflammatory genotype
3. Sex (differential regulation of inflammation)
Hypothesis
Breedtestrategie
Renal function decline is modified by CCL2 -2518 A/G in an albuminuria and sex dependent manner
Research population (1)
Breedtestrategie
PREVEND (n=8502)General population-basedEnriched for albuminuria
Selection: Succesful genotype, Caucasian descent(n=7504)
Follow-up: 4 years on average
Renal function:BSA adjusted Creatinine clearance (CrCl)based on serum Cr and 2x24h urine concentractions
Renal damage/Inflammation:Urinary albumine excretion (2x24h)
-100.00 0 100.00
delta CrCl
0
250
500
750
Cou
nt
-100.00 0 100.00
delta CrCl
0
250
500
750
Cou
nt
Research population (2)
Breedtestrategie
Main outcome parameter:
Renal Function Decline (RFD) : More than 10% decrease in CrCl since baseline
Baseline characteristics by CCL2 -2518 A/G
BreedtestrategieTable 1. Baseline characteristics by CCL2 -2518 A/G genotype
AA AG GG
Males N 1940 1458 292 Age (years) 51 ± 13 51 ± 13 50 ± 13 SBP (mmHg) 134 ± 18 134 ± 19 133 ± 18 DBP (mmHg) 77 ± 9 77 ± 10 77 ± 10
CrCl (ml/min/1.73 m2)
95 ± 21 94 ± 21 94 ± 21
UAE (mg/L/24h) 10.9 (7.1 - 23) 10.6 (6.9 - 22.9) 10.7 (6.8 - 22.9) CRP (mmol/L) 1.2 (0.6 - 2.7) 1.4 (0.6 - 3) 1.1 (0.5 - 2.5) BMI 26 ± 4 26 ± 4 26 ± 3 BSA 2 ± 0.2 2 ± 0.2 2.1 ± 0.2 Smoking (%) 38 36 36 TC (mmol/L) 5.7 ± 1.1 5.7 ± 1.1 5.7 ± 1.1 HDL-c (mmol/L) 1.2 ± 0.3 1.2 ± 0.3 1.2 ± 0.3
ΔCrCl (ml/min/1.73m2)
-2.9 ± 20.5 -1.9 ± 20.6 -2.6 ± 20.8
Females N 1982 1550 282 Age (years) 48 ± 12 48 ± 12 49 ± 13 SBP (mmHg) 124 ± 21 124 ± 20 127 ± 22 DBP (mmHg) 71 ± 9 71 ± 9 71 ± 9 OCC (%) 26 25 24
CrCl (ml/min/1.73 m2)
90 ± 21 91 ± 20 89 ± 20
UAE (mg/L/24h) 8.3 (5.8 - 14.1) 8.5 (5.9 - 14.3) 8.9 (6.1 - 18.3) CRP (mmol/L) 1.4 (0.6 - 3.2) 1.4 (0.6 - 3.2) 1.3 (0.5 - 3.5) BMI 26 ± 5 26 ± 5 26 ± 5 BSA 1.8 ± 0.1 1.8 ± 0.2 1.8 ± 0.2 Smoking (%) 39 38 35 TC (mmol/L) 5.7 ± 1.2 5.6 ± 1.1 5.7 ± 1.2 HDL-c (mmol/L) 1.5 ± 0.4 1.5 ± 0.4 1.5 ± 0.4
ΔCrCl (ml/min/1.73m2)
0.1 ± 18.3 -0.9 ± 18.6 -1.1 ± 19.9
Shown are arithmetic means and standard deviations, median and 25th – 75th percentiles in case of skewed distributions, and group percentages. No characteristics differed significantly between genotype groups.
Table 2. Impaired renal function and renal function decline by genotype
AA AG GG P
Males IRF0 4.2 (81/1907) 6.3 (90/1440) 6.4 (18/283) 0.024
RFD 34.2 (515/1504) 32.7 (370/1130) 29.8 (65/218) n.s. IRF1 6.3 (96/1520) 5.6 (64/1137) 5.4 (12/222) n.s.
Females IRF0 5.6 (108/1941) 5.6 (85/1505) 7 (19/273) n.s. RFD 27 (413/1530) 30.6 (358/1170) 31.3 (67/214) n.s.
IRF1 6.2 (96/1544) 5.5 (65/1190) 5.9 (13/219) n.s.
IRF: impaired renal function (CrCl < 60 ml/min/1.73m2); RFD: more than 10% decline in CrCl during follow-up.
Renal function and change by genotype
Breedtestrategie
Breedtestrategie -RFD +RFD P
Males Age (yrs) 50 +/- 12 52 +/- 13 <0.05
SBP (mmHg) 132 +/- 17 135 +/- 19 <0.05 Smoking (%) 34.5 37.8 0.08 BMI 26.2 +/- 3.5 26.3 +/- 3.4 n.s. TC (mmol/L) 5.7 +/- 1.1 5.6 +/- 1.1 n.s. HDL-c (mmol/L) 1.16 +/- 0.3 1.15 +/- 0.3 n.s. (V)LDL-c (mmol/L) 4.5 +/- 1.2 4.5 +/- 1.1 n.s.
TGL (mmol?L) 1.6 +/- 1.2 1.6 +/- 1.1 n.s. CrCl (ml/min/1.73m2) 91.3 +/- 18.6 103.2 +/- 20.9 <0.05 delta CrCl (ml/min/1.73m2) 8 +/- 14.5 -23.5 +/- 13.4 <0.05 lnlnUAE 0.9 +/- 0.3 1 +/- 0.4 <0.05 MA (%) 15 17.7 0.07 CRP (mmol/L) 2.3 +/- 3.8 2.7 +/- 4.6 <0.05
CCL2 -2518 (%) n.s. AA 52 54.2 AG 40 38.9 GG 8 6.8 CCL2 -2518 (%) n.s. AG+GG 48 45.8
Females Age (yrs) 48 +/- 12 49 +/- 12 <0.05 SBP (mmHg) 123 +/- 19 125 +/- 22 <0.05 Smoking (%) 35.8 39 0.1 BMI 25.8 +/- 4.7 26.1 +/- 4.6 n.s. TC (mmol/L) 5.6 +/- 1.2 5.7 +/- 1.1 n.s. HDL-c (mmol/L) 1.51 +/- 0.4 1.46 +/- 0.4 <0.05
(V)LDL-c (mmol/L) 4.1 +/- 1.3 4.2 +/- 1.2 n.s. TGL (mmol?L) 1.2 +/- 0.7 1.3 +/- 0.9 <0.05 CrCl (ml/min/1.73m2) 87 +/- 17 99.5 +/- 21.9 <0.05 delta CrCl (ml/min/1.73m2) 8 +/- 12.9 -21.3 +/- 13 <0.05 lnlnUAE 0.8 +/- 0.3 0.8 +/- 0.3 <0.05 MA (%) 7.7 10.6 0.01
CRP (mmol/L) 2.6 +/- 4.4 3.2 +/- 5.5 <0.05 CCL2 -2518 0.08 AA 53.8 49.3 AG 39.1 42.7 GG 7.1 8 CCL2 -2518 0.027
AG+GG 46.2 50.7
Baseline characteristics by RFD
Breedtestrategie
Table 3. Logistic regression model of Renal Function Decline
OR P
Age (yrs) 1.03 <0.0001 BMI 0.97 <0.01
Smoking (Yes) 1.15 <0.05 SBP (mmHg) 1.01 <0.05 CrCl0 (ml/min/1.73m2) 1.04 <0.0001 ltUAE 1.34 <0.01 CRP (mmol/L) 1.02 <0.01
ltUAE: double natural logistic transformed UAE (mg/L/24h).
Logistic regression model for RFD
Note that in this model sex and CCL2 -2518 genotype are not independent factors
Breedtestrategie
Multivariable fractional polynomial model for RFD
Table 4. Multivariable fractional polynomial model for RFD
RFD OR Std. Err. z P [95% Conf.Interval]
Age 1.004287 0.000387 11.1 0 1.003529 1.005046 SBP 1.004076 0.001975 2.07 0.039 1.000213 1.007954 BMI 9771328 0.008494 -2.66 0.008 0.960625 0.993924 Smoking 1.16629 0.077666 2.31 0.021 1.023583 1.328893 frCrCL_1 3.08E-07 9.67E-07 -4.77 0 6.50E-10 0.000146 frCrCl_2 202957.3 339270.3 7.31 0 7664.907 5374058 ltUAE 1.101698 0.201094 0.53 0.596 0.770357 1.575552 CRP 1.016894 0.007196 2.37 0.018 1.002888 1.031096 Sex 0.874998 0.217463 -0.54 0.591 0.537599 1.42415 CCL2 -2518 G+ 0.524823 0.137238 -2.47 0.014 0.314362 0.876186 sex*ltUAE 1.168397 0.315529 0.58 0.564 0.68821 1.983626 sex*CCL2 2.5841 0.91073 2.69 0.007 1.295135 5.155887 ltUAE*CCL2 1.890192 0.498371 2.41 0.016 1.127397 3.169092 CCL2*sex*ltUAE 0.438736 0.166384 -2.17 0.03 0.20864 0.922591
A-hom ozygotes G-ca rriers
1 2 3 4 5 6 7 8 9 10
Tentiles of UAE (transformed)
0,25
0,30
0,35
0,40
0,45
Pre
dic
ted
p o
f d
ecre
ased
filt
rati
on
M ale Fem ale
1 2 3 4 5 6 7 8 9 10
Tentiles of UAE (transformed)
Multivariable fractional polynomial model for RFD
Breedtestrategie
Correlations
1 ,719 **
,000
166593808,9 86494005,816
21093,164 13681,431
7899 6323
,719 ** 1
,000
86494005,816 144101986,2
13681,431 22739,780
6323 6338
Pearson Correlation
Sig. (2-tailed)
Sum of Squares andCross-products
Covariance
N
Pearson Correlation
Sig. (2-tailed)
Sum of Squares andCross-products
Covariance
N
Mean Urinary AlbuminExcretion (UAE)
Mean Urinary AlbuminExcretion (UAE)
Mean UrinaryAlbuminExcretion
(UAE)
Mean UrinaryAlbuminExcretion
(UAE)
Correlation is significant at the 0.01 level (2-tailed).**.
Correlations nc1 vs nc2
Correlations
1 ,528 **
,000
7349 5766
,528 ** 1
,000
5766 5832
Pearson Correlation
Sig. (2-tailed)
N
Pearson Correlation
Sig. (2-tailed)
N
Creatinine clearance(ml/min/1,73m**2)
Creatinine clearance(ml/min/1,73m**2) NC2
Creatinineclearance
(ml/min/1,73m**2)
Creatinineclearance
(ml/min/1,73m**2) NC2
Correlation is significant at the 0.01 level (2-tailed).**.
UAE
CrCl
Breedtestrategie
Males AA AG GG
ORN
case/controlOR P N OR P N Overall P
CrCl (measured) 1 81/1826 1.5 0.01 90/1350 1.53 0.113 18/265 0.025
CG 1 69/1853 0.92 0.67 48/1397 0.58 0.2 6/279 0.435
MDRD 1 40/1896 0.86 0.56 26/1428 0.66 0.44 4/286 0.67
Females
CrCl (measured) 1 108/1833 1.01 0.92 85/1420 1.3 0.35 19/254 0.645
CG 1 103/1848 0.84 0.28 68/1453 1.12 0.564 17/261 0.381
MDRD 1 18/1956 1.36 0.37 19/1522 0.39 0.36 1/279 0.364
Impaired renal function – univariate Measured versus predicted
Breedtestrategie
Logistic regression Number of obs = 5306 LR chi2(10) = 329.43 Prob > chi2 = 0.0000Log likelihood = -2841.3476 Pseudo R2 = 0.0548------------------------------------------------------------------------------cock_del~c_b | Odds Ratio Std. Err. z P>|z| [95% Conf. Interval]-------------+---------------------------------------------------------------- Iage___1 | 1.006379 .0004285 14.94 0.000 1.00554 1.007219 Icock__1 | 4.571734 .8421515 8.25 0.000 3.186269 6.55963 Icock__2 | .0035736 .0018236 -11.04 0.000 .0013144 .0097159 sex | 2.029337 .5176993 2.77 0.006 1.230853 3.345817 ccl22518_g | .8152031 .2230756 -0.75 0.455 .4768035 1.393773 Ilnln__1 | 1.394434 .2640953 1.76 0.079 .9620257 2.021199 Iint___1 | .7489486 .2049527 -1.06 0.291 .4380437 1.280521int_SEX_CCL2 | 1.304824 .469326 0.74 0.459 .6447441 2.640685 Iint_a_1 | 1.356773 .3682877 1.12 0.261 .7969918 2.309727 Iint_b_1 | .7595832 .2913697 -0.72 0.473 .3581473 1.610976------------------------------------------------------------------------------
Deviance: 5682.695.
Multivariable fractional polynomial model for RFD (Cockroft)
Breedtestrategie
AAAGGG
CCL2 SNPolymorphism -2518
Ba rs s how % of Cases = 1 ,00
0,00 1,00
MUAE_15
2
4
6
8
den
ovo
Co
ckr
60
n=1036 n=781 n=552 n=409 n=71
M ale Fem ale
0,00 1,00
MUAE_15
n=1267 n=974 n=166 n=347 n=277 n=59
De Novo IRFBreedtestrategie
De novo Cockroft < 60 NC2 :------------------------------------------------------------------------------cock_2_de~60 | Odds Ratio Std. Err. z P>|z| [95% Conf. Interval]-------------+---------------------------------------------------------------- Iage___1 | 1.138783 .0110555 13.39 0.000 1.117319 1.160658 sex | 1.399462 .2379566 1.98 0.048 1.00283 1.952965 ccl22518_g | .947831 .156412 -0.32 0.745 .6859063 1.309776 UAE15 | 1.413706 .2426113 2.02 0.044 1.009907 1.97896------------------------------------------------------------------------------Deviance: 1181.832.
------------------------------------------------------------------------------cock_2_de~60 | Odds Ratio Std. Err. z P>|z| [95% Conf. Interval]-------------+---------------------------------------------------------------- Iage___1 | 1.138128 .011092 13.28 0.000 1.116594 1.160077 sex | 1.758046 .5305301 1.87 0.062 .9731076 3.176139 ccl22518_g | .9569597 .3532386 -0.12 0.905 .4641871 1.972851 UAE15 | 1.852891 .586917 1.95 0.052 .9959224 3.447262int_SEX_CCL2 | .8027043 .3740964 -0.47 0.637 .322001 2.001031intUAE15_SEX | .3144433 .1678408 -2.17 0.030 .1104576 .8951366intUAE15_C~2 | .7700184 .3677037 -0.55 0.584 .3020163 1.963233intUAE15_S~2 | 4.583692 3.334675 2.09 0.036 1.101436 19.07531------------------------------------------------------------------------------Deviance: 1174.213.
UAE 15
UAE15*CCL2*SEX
Conclusions
Breedtestrategie
Mild to severe renal function decline (RFD) in the general populationis associated with a complex interaction between gene and environment
Inflammation plays a role in RFD as suggested by the observed interaction
Results are suggestive of an interaction between the CCL2 promoter SNP and albuminuria as an independent predictor of RFD and de novo IRF, that is different in males and females.
The exact nature of this relationship is unclear.
Discussion (1)
Breedtestrategie
Limitations:
Definition of renal function decline
There is no golden standard for estimation of renal function decline. Due to the nature of the analyses, a three-way interaction including a SNP, there’s a possible conflict between biological relevance and statistical power. A decline of more than 10% is aplausible estimate, since it will separate “normal” decline from putative pathological decline.
Exactness of CrCl-measurements
Regression to the mean and technical/compliance errors during collection of urine to estimate CrCl provide a statistical challenge. deltaCrCl shows a normal distrbution curve with CrCl-increase matching decrease in proportion. However, correlation of the two points is at a very low.
Discussion (2)
Breedtestrategie
Limitations:
Follow-up time and population
The observed univariate association of genotype with impaired renal function (<60 ml/min) in males is not found at the second visit. However, a large number of people that were at CV/renal risk at baseline did not return for the second visit. Thus, a high risk group was lost to follow-up.
A period of 4 years was the ultimate goal between first and second visit, yet there’s individual variety in actual time between first and secondVisit. Correcting our results for actual follow-up time did not alter the results.
Theoretical Discussion (2)Breedtestrategie
Exit of participants during period NC1-NC2 bij BP class, AHT and IRF (<60ml)
0
10
20
30
40
50
60
-AHT +AHT -AHT +AHT
-IRF +IRF
%<120/<80
120-139/80-89
140-159/90-99
>=160/>=100
3,00 4,00 5,00 6,00
DeltaYearsNC1NC2
0
250
500
750
Co
un
t
3,00 4,00 5,00 6,00
age_2b_1
0
1000
2000
3000
Co
un
t
Top Related